Delivery Order SPE2DB22D1106-SPE2DB25FFDF2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $4,606.47. This delivery order represents a firm fixed-price, non-set-aside contract to be completed by September 15, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) at a ceiling value of $2,378.33. This competitively awarded, firm fixed-price delivery order is scheduled for ultimate completion on August 29, 2025, with performance to be executed at AmerisourceBergen's Conshohocken, Pennsylvania location. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Gemtesa 75 mg tablets (90-count package) valued at $9,243.98 under a firm fixed-price contract. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The award was made on a competitive basis with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) under a firm fixed price contract valued at $43,743.38. This is a non-set-aside, competitively awarded delivery order with an ultimate completion date of September 17, 2025. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $7,385.86. This firm fixed-price delivery order, with an ultimate completion date of October 21, 2025, represents a non-competitive award under the company's existing indefinite delivery contract vehicle with DLA Troop Support Medical. The order will be fulfilled from AmerisourceBergen's Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $48,927.46 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (90-count units) on April 23, 2025, with an ultimate completion date of April 24, 2025. This firm fixed price contract represents a non-competitive delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $7,531.09 to AmerisourceBergen Drug Corp for the supply of Gemtesa 75 mg tablets (30-count units) on September 4, 2025, with completion expected by September 5, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Gemtesa 75 mg tablets (90-count units) with a ceiling value of $39,591.27. This firm fixed-price delivery order, which is expected to be completed by September 29, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award involved no set-aside designation, indicating it was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Gemtesa 75 mg tablets (30-count units) with a ceiling value of $8,301.73. This firm fixed price delivery order, which is scheduled for completion by September 4, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was made through open competition with no set-aside designation,...
- The Defense Logistics Agency awarded a $7,642.01 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Gemtesa 75 mg tablets (90-count package) with completion targeted for September 10, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFDF2Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Gemtesa 75 mg tablets (90-count packages) under a firm fixed-price contract with a ceiling value of $2,079.50. This is a competitive, non-set-aside award with an ultimate completion date of August 15, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency. The company maintains a robust federal contract portfolio delivering brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This award for Gemtesa, a pharmaceutical product used in medical treatment, exemplifies AmerisourceBergen's role as a primary supplier within the DLA Medical Supply Chain, providing essential medications to support Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 8/14/25 |